Drug intelligence / Profile preview

Yan's Jiangzhi Decoction

Development stage: Preclinical
Lead developer: Kaken Pharmaceutical
Administration: Oral

Overview

Yan's Jiangzhi Decoction is a Traditional Chinese Medicine (TCM) herbal formulation currently undergoing a prospective randomized controlled trial for the treatment of dyslipidemia complicated with carotid atherosclerosis. While its specific mechanism is not detailed in the provided context, similar "Jiangzhi Decoction" formulations have been shown to regulate nuclear receptor transcription and lipid metabolism, affecting targets such as PPARα, LXRα, and HNF4α, leading to reduced lipid accumulation and regulated cholesterol and triglyceride levels.

Other names: Yanshi Jiangzhi Prescription颜氏降脂方

Targets

NR1H3 (Liver X receptor beta)HNF4A (Hepatocyte nuclear factor 4 alpha)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on Yan's Jiangzhi Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yan's Jiangzhi Decoction.

Explore the full profile